Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CARA |
---|---|---|
09:32 ET | 1516 | 0.649 |
09:34 ET | 401 | 0.6649 |
09:41 ET | 100 | 0.6417 |
09:48 ET | 200 | 0.648 |
09:50 ET | 600 | 0.641247 |
09:56 ET | 310 | 0.644499 |
09:57 ET | 200 | 0.6422 |
09:59 ET | 100 | 0.6401 |
10:03 ET | 1731 | 0.6445 |
10:10 ET | 3200 | 0.64 |
10:12 ET | 1000 | 0.64 |
10:15 ET | 17931 | 0.63913 |
10:24 ET | 1000 | 0.63 |
10:26 ET | 100 | 0.6349 |
10:28 ET | 1669 | 0.634951 |
10:30 ET | 2100 | 0.63 |
10:33 ET | 881 | 0.631 |
10:35 ET | 3000 | 0.6399 |
10:39 ET | 4500 | 0.6306 |
10:44 ET | 3620 | 0.6344 |
10:48 ET | 500 | 0.63 |
10:55 ET | 200 | 0.63 |
10:57 ET | 507 | 0.63 |
11:02 ET | 157 | 0.6387 |
11:06 ET | 100 | 0.6298 |
11:09 ET | 100 | 0.6246 |
11:11 ET | 200 | 0.6245 |
11:15 ET | 700 | 0.6288 |
11:18 ET | 2395 | 0.6245 |
11:20 ET | 1120 | 0.6215 |
11:24 ET | 282 | 0.6215 |
11:26 ET | 100 | 0.6215 |
11:27 ET | 2900 | 0.63 |
11:29 ET | 100 | 0.63 |
11:36 ET | 3250 | 0.622 |
11:38 ET | 100 | 0.622 |
11:42 ET | 100 | 0.6215 |
11:44 ET | 200 | 0.6301 |
11:51 ET | 650 | 0.6215 |
11:58 ET | 3369 | 0.6215 |
12:02 ET | 400 | 0.6215 |
12:05 ET | 100 | 0.6215 |
12:07 ET | 100 | 0.6215 |
12:12 ET | 170 | 0.6386 |
12:14 ET | 100 | 0.6215 |
12:16 ET | 1500 | 0.635 |
12:18 ET | 100 | 0.622 |
12:20 ET | 4477 | 0.6393 |
12:32 ET | 599 | 0.639399 |
12:36 ET | 989 | 0.6394 |
12:41 ET | 250 | 0.622 |
12:43 ET | 300 | 0.6307 |
12:52 ET | 260 | 0.6231 |
12:56 ET | 558 | 0.6263 |
12:57 ET | 645 | 0.6306 |
01:01 ET | 100 | 0.6251 |
01:06 ET | 200 | 0.6251 |
01:08 ET | 200 | 0.6251 |
01:12 ET | 1300 | 0.622 |
01:14 ET | 300 | 0.6299 |
01:19 ET | 1837 | 0.6216 |
01:21 ET | 639 | 0.6215 |
01:24 ET | 200 | 0.6215 |
01:26 ET | 3182 | 0.6201 |
01:28 ET | 16200 | 0.6217 |
01:30 ET | 996 | 0.6121 |
01:32 ET | 322 | 0.6216 |
01:33 ET | 2600 | 0.62 |
01:35 ET | 542 | 0.613 |
01:39 ET | 600 | 0.61685 |
01:42 ET | 8200 | 0.612 |
01:44 ET | 100 | 0.613 |
01:46 ET | 200 | 0.613 |
01:48 ET | 17595 | 0.6213 |
01:50 ET | 6655 | 0.6215 |
01:51 ET | 200 | 0.6214 |
01:55 ET | 4308 | 0.6195 |
01:57 ET | 100 | 0.61995 |
02:00 ET | 4240 | 0.621 |
02:02 ET | 200 | 0.6184 |
02:04 ET | 100 | 0.6215 |
02:06 ET | 100 | 0.62075 |
02:08 ET | 10000 | 0.62 |
02:09 ET | 100 | 0.61905 |
02:18 ET | 100 | 0.61905 |
02:20 ET | 400 | 0.6215 |
02:24 ET | 300 | 0.6189 |
02:26 ET | 100 | 0.61625 |
02:29 ET | 200 | 0.611 |
02:31 ET | 400 | 0.611 |
02:36 ET | 803 | 0.616251 |
02:38 ET | 1123 | 0.611 |
02:40 ET | 500 | 0.611 |
02:42 ET | 5404 | 0.61 |
02:44 ET | 200 | 0.61 |
02:45 ET | 600 | 0.6215 |
02:49 ET | 3590 | 0.62 |
02:51 ET | 100 | 0.6215 |
02:54 ET | 100 | 0.62 |
02:56 ET | 200 | 0.62 |
02:58 ET | 3486 | 0.62075 |
03:02 ET | 462 | 0.6153 |
03:03 ET | 100 | 0.6109 |
03:05 ET | 400 | 0.6106 |
03:07 ET | 300 | 0.60985 |
03:09 ET | 200 | 0.6128 |
03:12 ET | 200 | 0.61 |
03:14 ET | 4477 | 0.6163 |
03:16 ET | 100 | 0.61315 |
03:18 ET | 680 | 0.6144 |
03:20 ET | 300 | 0.6144 |
03:21 ET | 100 | 0.6144 |
03:23 ET | 500 | 0.6163 |
03:25 ET | 1700 | 0.6214 |
03:27 ET | 5000 | 0.6214 |
03:30 ET | 5300 | 0.6214 |
03:34 ET | 100 | 0.6125 |
03:36 ET | 200 | 0.6125 |
03:38 ET | 300 | 0.6125 |
03:39 ET | 300 | 0.6125 |
03:41 ET | 400 | 0.6134 |
03:43 ET | 400 | 0.6134 |
03:45 ET | 500 | 0.6134 |
03:48 ET | 400 | 0.6134 |
03:50 ET | 2491 | 0.626751 |
03:52 ET | 1500 | 0.6207 |
03:54 ET | 300 | 0.6207 |
03:56 ET | 8800 | 0.6238 |
03:57 ET | 1791 | 0.6164 |
03:59 ET | 18361 | 0.6242 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Cara Therapeutics Inc | 36.3M | -0.3x | --- |
ImmuCell Corp | 33.6M | -8.9x | --- |
Aadi Bioscience Inc | 43.2M | -0.7x | --- |
SQZ Biotechnologies Co | 1.3M | 0.0x | --- |
Turnstone Biologics Corp | 65.0M | -0.8x | --- |
Viaderma Inc | 7.7M | 0.0x | --- |
Cara Therapeutics, Inc. is a development-stage biopharmaceutical company. The Company is focused on treatment paradigm to improve the lives of patients suffering from chronic pruritus. It is developing an oral formulation of difelikefalin, a selective, predominantly peripherally acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated with Notalgia Paresthetica (NP), a common, underdiagnosed neuropathy affecting the upper back. It is conducting Phase II/III Clinical Program in NP. The program is comprised of two studies - KOURAGE 1 and KOURAGE 2, which are double-blind, placebo-controlled, eight-week studies with patients allowed to roll-over into open-label 52-week extensions. It has developed an IV formulation of difelikefalin, for the treatment of moderate-to-severe pruritus associated with advanced chronic kidney disease in adults undergoing hemodialysis. The IV formulation is out-licensed worldwide.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $36.3M |
---|---|
Revenue (TTM) | $16.9M |
Shares Outstanding | 54.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.77 |
EPS | $-2.26 |
Book Value | $1.05 |
P/E Ratio | -0.3x |
Price/Sales (TTM) | 2.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -729.19% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.